Neurology & Brain Disorders Clinical Trials Update: Week 18, 2026

Published May 1, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

This Phase 3 trial is testing lecanemab, an antibody treatment, in people with early Alzheimer's disease. The goal is to see if lecanemab can slow down memory loss and thinking problems, potentially helping patients maintain their quality of life longer. The study is active but not recruiting, with results expected after 18 months of treatment from participants around the world.

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

This global Phase 3 trial is investigating trontinemab, a monoclonal antibody, for people showing early symptoms of Alzheimer's disease. If successful, this treatment may slow cognitive decline during the early stages, giving patients more time with clearer thinking. The study is currently recruiting and will assess outcomes over about 72 weeks.

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

This Phase 3 trial focuses on people in the very early or preclinical stages of Alzheimer's disease, when symptoms are not yet obvious but brain changes are present. It is testing whether lecanemab can slow the buildup of harmful proteins and delay cognitive decline. The study is active but not recruiting, with long-term results expected after about four years of treatment.

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)

This trial is exploring a new combination treatment to help reduce agitation in adults with Alzheimer's disease. Agitation can be very distressing for both patients and caregivers, so finding a safe and effective option could improve daily life. The study is currently recruiting participants in several countries, including the United States, and results are expected after 14 weeks of treatment.

GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)

This study is testing a new drug called mazdutide in people with type 2 diabetes who also have early dementia. Since diabetes can increase the risk of cognitive problems, this treatment aims to slow memory and thinking decline in this group. The trial is recruiting in China and plans to complete after about 76 weeks of treatment.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.